Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
SAMJIN PHARMACEUTICAL CO.,LTD Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.	South Korea	005500
SAMSUNG BIOLOGICS CO.,LTD. A CDMO providing end-to-end development and manufacturing services for the biopharma industry.	South Korea	207940
Sana Biotechnology, Inc. Engineering cells as medicine to repair genes and treat cancer, diabetes, and autoimmune disorders.	United States of America	SANA
SanBio Company Limited Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.	Japan	4592
SANGAMO THERAPEUTICS, INC Developing genomic cures for severe genetic diseases using proprietary zinc finger technology.	United States of America	SGMO
SANIGEN Co., Ltd. Provides food safety solutions and genetic diagnostics for the entire food industry.	South Korea	188260
Sanofi A global biopharma firm researching and developing innovative medicines and vaccines for the world.	United States of America	SNY
Sanofi Global biopharma firm researching, developing & marketing prescription medicines & vaccines.	France	SAN
SANTEN PHARMACEUTICAL CO.,LTD. A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.	Japan	4536
Santhera Pharmaceuticals Holding AG Develops innovative medicines for rare neuromuscular and mitochondrial disorders.	Switzerland	SANN